The extract below is taken from Judge Sweet's opinion, in which he granted
summary judgment to the petitioners (AMP et. al.) against Myriad
Genetics.
(Case 1:09-cv-04515-RWS, Document 255, Filed
03/29/2010). This extract covers the ‘purification’ cases, with
discussion of the denial of patentability to pure tungsten,
uranium and
vanadium, adrenaline, prostoglandin, vitamin
B12.
District Judge Robert W. Sweet is the trial
judge, in the Southern District of New York, before whom the plaintiffs
represented by ACLU and PubPat brought their case against Myriad
Genetics
______
Myriad has relied heavily on the holding of
the
Honorable Learned Hand in Parke-Davis & Co. v. H.K. Mulford
Co.
189 F.2d 95
(S.D.N.Y. 1911).46
In
Parke-Davis, Judge
Hand considered a challenge to the validity of a
patent
114
claiming an adrenaline compound that had been
isolated and
purified from animal suprarenal glands. Id. at 97. It
had
been known that suprarenal glands in powdered form had
hemostatic,
blood-pressure-raising and astringent
properties, but could not be used for
those purposes in
gross form. The isolated adrenaline, however, possessed
the
desired therapeutic properties and could be
administered to
humans.
Although Myriad argues that the holding in
Parke-Davis
establishes that the purification of a natural
product necessarily renders it
patentable, the opinion,
read closely, fails to support such a conclusion.
The
question before the court in Parke-Davis was one of novelty
(a
modern-day § 102 question), not of patentable subject
matter (the §
101 question before this Court). In framing
the issue, Judge Hand observed
that, “[the validity of the
claims] is attacked, first, because they are
anticipated in
the art; and second, for a number of technical
grounds
which I shall take up in turn.” Id. at 101
(emphasis
added). He went on to conclude that the patented purified
extract was
not, in fact, different from the prior art
“only for a degree of
purity,” but rather was a different
chemical substance from that found in
the prior art. Id.
115
at 103 (observing that
“no one had ever isolated a
substance [adrenaline] which was not in salt
form” and that
“the [claimed] base [form of adrenaline] was an
original
production of [the patentee's]”). Thus, Judge Hand held
that the
purified adrenaline was not anticipated by the
prior art, namely, the ground
paradrenal gland that was
known to possess certain beneficial properties.
See Merck
& Co. v. Olin Mathieson Chem. Corp., 253 F.2d 156, 162
(4th
Cir. 1958) (“It was further held [in Parke-Davis] that
the
invention was not anticipated, though the principle was
known to exist in
the suprarenal glands.”).
Only after concluding that the claimed
purified
adrenaline was novel over the prior art did Judge Hand
offer, as dicta,
the statement to Which Myriad cites: “But,
even if it were merely an
extracted product without change,
there is no rule that such products are not
patentable.”
Id. at 103. While the accuracy of this statement at
the
time was written is dubious in light of American Wood-Paper
(to which
Judge Hand did not cite) it is certainly no
longer good law in light of
subsequent Supreme Court cases,
which, as noted above, require that a claimed
invention
possess “markedly different characteristics” over
products
existing in nature in order for it to constitute
patentable
116
subject matter.47
Chakrabarty, 447 U.S. at 310;
see also
Funk Bros., 333 U.S. at 130-32. By the same token, Judge
Hand's
suggestion that a claimed invention was patentable
since it was a “new
thing commercially and
therapeutically,” Parke-Davis, 189 F.2d at
103, is firmly
contradicted by subsequent case law establishing that
“it
is improper to consider whether a claimed element or step
in a process
is novel or nonobvious, since such
considerations are separate
requirements” when evaluating
whether a claim is patent-eligible subject
matter.
Prometheus, 581 F.3d at 1343; see also Bergy, 596 F.2d
at
960-61. Such an approach would also be inconsistent with
the Supreme Court's
rejection of the patentability of the
commercially useful mixture of bacteria in
Funk Brothers,
the refined cellulose in American Wood-Paper, and
the
electromagnetic communication devices in O'Reilly v. Morse,
56 U.S.
(15 How.) 62 (1853).
The distinction between considerations of
novelty
and patentable subject matter similarly undermines Myriad's
reliance on
Bergstrom and In re Kratz, 592 F.2d 1169
(C.C.P.A. 1979), both of
which presented issues of novelty
117
and anticipation rather
than the question of patentable
subject matter. In Bergstrom, the
C.C.P.A. considered an
appeal from a rejection by the Board of Patent
and
Interferences (“BPAI”) of a patent claiming the
purified
rostaglandins PGE2 and PGE3 that had
been
extracted from
human or animal prostate glands. 427 F.2d at 1398.
Although
the BPAI cited § 101 in its rejection, the
C.C.P.A. recognized the issue as
a § 102 question of
novelty. Id. at 1400 (“Tested by the
conventional
evidentiary criteria or ‘conditions for
patentability’
relevant to the present factual situation which
Congress
has expressed in the various provisions of 35 U.S.C. §
102,
appellants are undoubtedly correct, for the Patent Office
has not been able
to … establish that the claimed
subject matter lacks
'novelty.’”);
see also id. at 1401
(“[T]he fundamental
error in the board's position, as we
see it, is the analysis and answer it gave
to the sole
issue it accurately posed - whether the claimed pure
materials are
novel as compared with the less pure
materials of the reference.”
(internal citation and
uotation marks omitted)). Indeed, the C.C.P.A. itself
has
subsequently recognized that Bergstrom is properly viewed
as a case
concerning novelty. Bergy, 596 F.2d at 961
(“Our research has
disclosed only two instances in which
118
rejections for lack
of novelty were made by the PTO under §
101.… In In re
Bergstrom we in effect treated the
rejection as if it had been made under
§ 102, obServing in
the process that ‘The word “new” in
§ 101
is defined and to
be construed in accordance with the provisions
of
§ 102.’”
(internal citation
omitted)).
Kratz examined the rejection of a patent claiming
a
substantially purified chemical compound naturally
occurring in strawberries,
called 2-methyl-2-pentenoic acid
(“2M2PA”). 592 F.2d at 1170. The
patentee had appealed
from the BPAI's determination that the purified
compound
was obvious over the prior art under § 103. See
_id.
Although there was some discussion about whether the
composition
claimed was a naturally-occurring compound, the
C.C.P.A. did not view the
question before it as a § 101
inquiry. Instead, the court treated the
appeal as a
question of novelty and anticipation pursuant to §
102.48
See, e.g., id. at 1174
(“It should be clear that an
119
anticipation rejection
in such a case is necessarily based
on a dual
footing.”).49
Finally, Merck & Co.,
Inc. v. Olin Mathieson
Chem. Corp., 253 F.2d 156, cited by Myriad, is
entirely
consistent with the principle set forth in Funk Brothers
and
American Fruit Growers that something derived from a
product of nature
must “possess a new or distinctive form,
quality, or property” in
order to become patentable subject
matter. Am. Fruit Growers, 283 U.S.
at 11.
In Merck, the
Fourth Circuit considered the validity of a patent
claiming
a Vitamin B12 composition useful for treating
pernicious
anemia. Id. at 157. Although naturally occurring
Vitamin
B12 produced in cows had known therapeutic properties and
was
commercially available, the court found the purified B12
Compositipn,
which was obtained from a microorganism,
patentable. In upholding the validity
of the patent, the
court held:
Every slight step in
purification does not
produce a new product. What is gained may be
the
120
old product, but with a greater
degree of purity.
Alpha alumina purified is still alpha alumina, In
re
Ridgway, 76 F.2d 602,[] and ultramarine from
which floatable impurities have
been removed is
still ultramarine, In re Merz, 97 F.2d 599
…
Id. at 163. Because the court concluded that
the purified
B12 was more than a “mere advance in the degree
of
purity of
a known product,” it determined that the claimed invention
was
entitled to patent protection. Id. at 164.
In sum, the clear
line of Supreme Court precedent
and accompanying lower court authorities,
stretching from
American Wood-Paper through to Chakrabarty,
establishes
that purification of a product of nature, without more,
cannot
transform it into patentable subject matter.
Rather, the purified product must
pogsess “markedly
different characteristics” in order to satisfy
the
requirements of § 101.
NOTES
46
The invocation of Judge Hand is frequently
practiced in this Circuit.
See, e.g.,United States v. Rigas, 583 F.3d
108, 121 n.3 (2d Cir. 2009)
(quoting Learned Hand for the proposition that
appellate courts may not
find facts); United States v. Parker, 554 F.3d
230 (2d Cir. 2009)
(quoting Learned Hand for his formulation of the requirements
of
conspiracy); In re City of New York, 522 F.3d 279, 284
(2d Cir.
2008)
(citing Learned Hand for his formulation of negligence);
In re
Hyman,
501 F.3d 61, 67 (2d Cir. 2007) (quoting at length Learned
Hand's
inconclusive discussion of the meaning of the
word
“defalcation” in 11
U.S.C. § 523(a)(4)); United States
v. Brand,
467 F.3d 179, 190 (2d Cir.
2006) (quoting Learned Hand's
definition of inducement by the
government); In re Enron Corp., 419 F.3d
115, 123 (2d Cir. 2005)
(quoting Learned Hand's critique of statutes of
limitations); Shannon
v._Jacobowitz, 394 F.3d 90, 95 (2d Cir. 2005)
(quoting Learned Hand's
instruction that “[w]ords are not pebbles in
alien
juxtaposition.&ellip;”);
Danahy v. Buscag1ia, 134 F.3d 1185,
1189 (2d Cir. 1998) (quoting
Learned Hand on the rationale for qualified
immunity). See a1so,
Remarks of the Honorable John N. Walker, Jr. Upon
Receiving the Learned
Hand Meda1 for Exce11ence in Federal Jurisprudence, 76
St. John's L.
Rev. 595, 596 (2002) (“Judge Hand is widely considered to
have been one
of the four greatest judges of the first half of the
twentieth
century.”); James L. Oakes, Personal Ref1ections on Learned
Hand and
the Second Circuit, 47 Stan. L. Rev. 387 (1995); Gerald
Gunther,
Learned Hand: the Man and the Judge (1994); Kathryn
Griffin,
Judge Learned Hand and the Ro1e of the Federa1 Judiciary
(1973);
Marvin Schick, Learned Hand's Court (1970);
Marcia Nelson, ed.,
The Remarkable
Hands: An Affectionate Portrait (1983); Hershel Shanks,
ed.,
The Art
and Craft of Judging: The Decisions of Judge Learned Hand
(1968).
Although Judge Hand once turned his back on the author of this
opinion
arguing before him on behalf of the Government, his opinion in
Parke-
Davis deserves careful review but brings to mind that oft
repeated
adage “Quote Learned, but follow Gus.” See
Oakes,
47 Stan. L. Rev. at
389 n.175. This author, confronted by genomics and
molecular biology,
also emphatically empathizes with Judge Hand's complaint
in
Parke-Davis
about his lack of knowledge of the rudiments of
chemistry.
See Parke-Davis, 189 F. at 114.
47
Notwithstanding Judge Hand's reputation,
see supra note 46, his
opinion in Parke-Davis was one of a
district court judge and does not
supersede contrary statements of the law by
the C.C.P.A. or the Supreme
Court.
48
The differences between the test applied
in Kratz and the “markedly
different” requirement set forth in
Chakrabarty
and other Supreme Court precedent further demonstrates
that
the Kratz court was engaged in a §
102 anticipation analysis and not
a § 101 statutory subject matter
analysis. See id. at 1174
(requiring, for a finding of anticipation,
that “the natural composition
must inherently contain the naturally
occurring compound” and that
“the claim must be of
sufficient breadth
to encompass both the known
natural composition and the naturally
occurring compound.”).
49
Bergy, also cited by Myriad,
considered the question of whether
microorganisms constituted patentable subject
matter, an issue
subsequently addressed by the Supreme Court in
Chakrabarty.
It did not
address the patentability of purified natural
products, and its
citation to Merck and Parke-Davis was only for
the purpose
of noting
that courts had upheld patents on pharmaceutical compounds
such as
vitamin B12 and adrenaline.
See Bergy, 596 F.2d at
974-75 & n.13.
[ Reply to This | Parent | # ]
|